Neurizon Enters Global Licensing Agreement with Elanco
Released
Released
Announcement PDF
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation
of NUZ-001
Highlights:
Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement
Provides worldwide rights for Neurizon to utilise Elanco’s intellectual property, providing exclusive
access to an extensive package of non-clinical studies and manufacturing data and outlines key terms for
a future supply agreement for GMP-compliant Monepantel
Provides a clear pathway for accelerated global commercialisation of NUZ-0011 and significantly de-risks
future global regulatory approval processes
The license agreement represents the first step in formalising Neurizon’s relationship with Elanco, with
the next step focused on finalising a supply agreement expected H2 CY 2025
02 July 2025 – Melbourne, Australia: Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the
Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative
diseases, is pleased to announce it has executed an exclusive global license agreement with Elanco Animal Health
Incorporated (Elanco; NYSE: ELAN) and affiliates for Monepantel, the active pharmaceutical ingredient in NUZ-001,
Neurizon’s lead investigational therapy in development for Amyotrophic Lateral Sclerosis (ALS) and other
neurodegenerative diseases in humans.
This license agreement represents a critical inflection point for Neurizon, further strengthening the Company’s
strategic outlook for the development, manufacturing and potential future commercialisation of NUZ-001. It also
significantly supports the Company’s regulatory foundations, providing ongoing access to critical animal safety data
and manufacturing data, key pillars required to support future clinical trials, potential regulatory approvals and global
market entry.
Dr. Michael Thurn, Managing Director and Chief Executive Officer, commented: “This license agreement with Elanco
marks a watershed moment in Neurizon’s journey to become a leader in the accelerated development of treatments
for neurodegenerative diseases. This strategic milestone provides exclusive access to a comprehensive package of
non-clinical studies and manufacturing data, dramatically reducing near-term development costs and accelerating
development timelines. All of this is in exchange for a nominal up-front payment, small back-ended regulatory
approval and commercial sale milestones and single-digit royalty payments on future global net sales. Neurizon is
now well-positioned to accelerate the path to market and advance new treatment options for people affected by
devastating neurodegenerative diseases.”
Mr. Sergio Duchini, Non-Executive Chairman, commented: “On behalf of the Board, I am pleased to endorse this
landmark agreement with Elanco, which represents a strategically significant step forward for Neurizon. This
agreement not only strengthens our clinical and regulatory position but also reflects our strong commitment to
accelerating the development of meaningful therapies for people living with neurodegenerative diseases. We are also
very happy to be making this important step in formalising our relationship with Elanco and look forward to building
on this foundation as we progress towards finalising a supply agreement later this year.”
Key Terms of the Licensing Agreement:
Exclusive Global Rights: Neurizon is granted exclusive global rights to Elanco’s data package and related
intellectual property for monepantel to develop and commercialise NUZ-001 and its related compounds for the
treatment, palliation, prevention, or cure of neurodegenerative diseases in humans.
Upfront Payment: A nominal upfront licensing fee is payable to Elanco upon execution of the agreement2.
1 NUZ-001 is Neurizon Therapeutics formulation of monepantel for use in neurodegeneration applications.
2 The amount is not material to Neurizon’s current cash position
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Milestone Payments: Total Development milestone payments for the initial and subsequent licensed products,
indications, or presentations of US$9.75 million and US$5.2 million, respectively. Elanco will also be eligible for
milestone payments of up to US $65 million based on sales milestones3.
Royalties: Elanco will receive tiered single-digit royalties on global net sales of licensed products.
Supply: The agreement outlines certain key terms, including duration and price, for the conclusion of a Supply
Agreement.
Supply Agreement
Neurizon and Elanco remain focused on finalising a supply agreement, with a follow-up announcement anticipated in
H2 CY 2025.
This next phase of the collaboration is expected to provide Neurizon with long-term, scalable source of GMPcompliant monepantel to support ongoing clinical development, regulatory submissions, and future global
commercialisation of NUZ-001.
-ENDSThis announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.
For further information, please contact:
Dr. Michael Thurn
Managing Director and Chief Execufive Officer
Neurizon Therapeufics Limited
enquiries@neurizon.com
+61 (3) 9692 7222
Lidija Damjanovic
Head of Markefing and Corporate Affairs
Neurizon Therapeufics Limited
lidija@neurizon.com
+61 (0) 425 700 504
Released through: Henry Jordan, Six Degrees Investor Relations, +61 (0) 431 271 538
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing
treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the
treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate
access to effective ALS treatments for patients while exploring NUZ-001’s potential for broader neurodegenerative
applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating
new horizons for patients and families impacted by complex neural disorders.
Neurizon Investor Hub
We encourage you to ufilise our Investor Hub for any enquiries regarding this
announcement or other aspects concerning Neurizon.
This plafform offers an opportunity to submit quesfions, share comments, and view
video summaries of key announcements.
To access Neurizon Investor Hub please scan the QR code or visit
hftps://investorhub.neurizon.com
Neurizon® is a registered trademark of Neurizon Therapeutics Limited
If triggered, the sales milestone payments will not fall due until six months after the first commercial sale. The remaining regulatory and
commercial milestone payments will become due 30 days after the relevant milestone is met.
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
3
Share your feedback
Discover